trending Market Intelligence /marketintelligence/en/news-insights/trending/5E_zVbX1w9FputCrYP20tw2 content esgSubNav
In This List

EMA grants PRIME access to BioMarin's hemophilia A therapy

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022

Blog

Insight Weekly: Challenges for European banks; Japan's IPO slowdown; carmakers' supply woes


EMA grants PRIME access to BioMarin's hemophilia A therapy

The European Medicines Agency granted access to the priority medicines regulatory initiative to BioMarin Pharmaceutical Inc.'s investigational gene therapy drug for severe hemophilia A, which causes increased bleeding and usually affects males.

The agency's Committee for Medicinal Products for Human Use determined the PRIME access was justified due to the therapy's preliminary clinical data in affected patients, supporting that a single IV administration results in sustained restoration of factor VIII activity, reduction of annualized bleeding rates and improved quality of life.